Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 68

Results For "strategy"

990 News Found

LISSUN raises ~$1 million in pre-Seed round from IvyCap Ventures and others
News | September 28, 2022

LISSUN raises ~$1 million in pre-Seed round from IvyCap Ventures and others

Funds raised will be used to develop technology and foster healthcare partnerships


Aptar Pharma collaborates with Fluidda
News | September 25, 2022

Aptar Pharma collaborates with Fluidda

The companies will leverage their respective proprietary technology platforms


Cadila and CII launches joint national campaign for rabies-free India by 2030
Public Health | September 24, 2022

Cadila and CII launches joint national campaign for rabies-free India by 2030

Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone


JB Pharma witness 20% growth in August 2022: IQVIA
News | September 22, 2022

JB Pharma witness 20% growth in August 2022: IQVIA

Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.


Parexel appoints Peyton Howell and Amy McKee
People | September 16, 2022

Parexel appoints Peyton Howell and Amy McKee

These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers


ProBioGen receives Employer of the Future and the Top Service awards
News | September 14, 2022

ProBioGen receives Employer of the Future and the Top Service awards

They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.


Lonza appoints Daniel Palmacci as President of the Cell & Gene Division
People | September 13, 2022

Lonza appoints Daniel Palmacci as President of the Cell & Gene Division

He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Clinical Trials | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


Merck invests € 130 million + to strengthen manufacturing capabilities in France
News | September 10, 2022

Merck invests € 130 million + to strengthen manufacturing capabilities in France

Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025